Oasmia Pharmaceutical will publish its Q1 report on September 9, 2020, at 08.00 am CEST.
The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Francois Martelet, CEO, and Michael af Winklerfelt, CFO. The presentation will be in English.
The conference call will be broadcast live on the web via the link:
https://tv.streamfabriken.com/oasmia-pharmaceutical-q1-2020-2021
Telephone number for the conference call is:
SE: +46850558375
UK: +443333009272
US: +18332498405
For more information:
Francois Martelet, CEO of Oasmia
Michael af Winklerfelt, CFO of Oasmia
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications
Jonathan Birt, Chris Welsh
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR17. Oasmia has been successful in moving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has received market authorization in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories. The company’s shares are traded on Nasdaq Stockholm (ticker: OASM). Visit www.vivesto.com for further information.